Thomas Decker, Prof.Dr. Study Chair Ravensburg Ingolf Juhasz-Böss, Prof.Dr. Study Chair Freiburg Elmar Stickeler, Prof.Dr. Study Chair Aachen Dirk Watermann, Prof.Dr. Study Chair Freiburg Anja Welt, Dr. Study Chair Essen Achim Wöckel, Prof.Dr. Study Chair Würzburg
1. Course of treatment (treatment reality). (Time Frame - 3 years per patient): Documentation of anamnestic data and therapy sequences.
Secondary outcome:
1. Best Response. (Time Frame - 3 years per patient): Documentation of response rates per line of treatment.
2. Progression-free survival. (Time Frame - 3 years per patient): Documentation of progression-free survival per line of treatment.
3. Overall survival. (Time Frame - 3 years per patient): Documentation of overall survival per line of treatment.
4. Health-related quality of life (Patient-reported outcome, PRO). (Time Frame - 3 years per patient): Functional Assessment of Cancer Therapy - Ovarian (FACT-O), a 39 item questionnaire
covering Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional
Well-Being and Ovarian Cancer Subscale
5. Health-related quality of life (Patient-reported outcome, PRO). (Time Frame - 3 years per patient): Functional Assessment of Cancer Therapy - Endometrial (FACT-En), a 43 item questionnaire
covering Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional
Well-Being and Endometrial Cancer Subscale
Ovarian cancer Female patients with high grade OC (advanced or metastatic epithelial ovarian, fallopian
tube and primary peritoneal cancer):
- with newly diagnosed FIGO stage IIb-IV OC who are starting systemic treatment,
independent of the treatment intention (adjuvant/curative or palliative) or
- with recurrent/relapsed disease, who received any previous systemic anti-tumor
treatment and who are now starting their systemic treatment for first
recurrent/relapsed disease.
Endometrial cancer Female patients with locally advanced and inoperable or metastatic EC (FIGO stage III-IV)
who are starting systemic first-line therapy.
